NEW YORK, May 22, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), today announced upcoming presentations of clinical data for TG-1101, the Company’s next generation, glycoengineered anti-CD20 monoclonal antibody and for TGR-1202, the Company’s novel, once-daily PI3k delta inhibitor, at the 19th Congress of the European Hematology Association (EHA), being held June 12 – 15, 2014 in Milan, Italy. Copies of the EHA abstracts are available online through the EHA meeting website at www.ehaweb.org.
Help employers find you! Check out all the jobs and post your resume.
